- Home
- EDSA vs BGLC Comparison
EDSA vs BGLC Comparison
Compare EDSA & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- BGLC
- Stock Information
- Founded
- EDSA 2015
- BGLC 2017
- Country
- EDSA Canada
- BGLC Malaysia
- Employees
- EDSA N/A
- BGLC N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- BGLC Medical Specialities
- Sector
- EDSA Health Care
- BGLC Health Care
- Exchange
- EDSA Nasdaq
- BGLC Nasdaq
- Market Cap
- EDSA 6.2M
- BGLC 5.8M
- IPO Year
- EDSA N/A
- BGLC N/A
- Fundamental
- Price
- EDSA $2.45
- BGLC $0.25
- Analyst Decision
- EDSA Strong Buy
- BGLC
- Analyst Count
- EDSA 1
- BGLC 0
- Target Price
- EDSA $21.00
- BGLC N/A
- AVG Volume (30 Days)
- EDSA 32.2K
- BGLC 1.5M
- Earning Date
- EDSA 05-09-2025
- BGLC 05-14-2025
- Dividend Yield
- EDSA N/A
- BGLC N/A
- EPS Growth
- EDSA N/A
- BGLC N/A
- EPS
- EDSA N/A
- BGLC N/A
- Revenue
- EDSA N/A
- BGLC $9,259,858.00
- Revenue This Year
- EDSA N/A
- BGLC N/A
- Revenue Next Year
- EDSA N/A
- BGLC N/A
- P/E Ratio
- EDSA N/A
- BGLC N/A
- Revenue Growth
- EDSA N/A
- BGLC N/A
- 52 Week Low
- EDSA $1.55
- BGLC $0.21
- 52 Week High
- EDSA $5.59
- BGLC $1.00
- Technical
- Relative Strength Index (RSI)
- EDSA 53.34
- BGLC 35.57
- Support Level
- EDSA $2.31
- BGLC $0.23
- Resistance Level
- EDSA $2.55
- BGLC $0.29
- Average True Range (ATR)
- EDSA 0.12
- BGLC 0.02
- MACD
- EDSA -0.02
- BGLC -0.01
- Stochastic Oscillator
- EDSA 48.28
- BGLC 20.22
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.